Senores Pharmaceuticals (SENORES) Fundamentals 2026 — P/E 52.8x, Revenue Analysis | SniperIQ
Senores Pharmaceuticals (SENORES) is a India-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₹6,417 Crore, trading at ₹1393.40 on the NSE. This SniperIQ fundamentals page covers Senores Pharmaceuticals's valuation (P/E 52.8x, P/B 5.9x), profitability (net margin 18.5%), revenue (₹633 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Senores Pharmaceuticals's market cap?
Senores Pharmaceuticals (SENORES) has a market capitalization of approximately ₹6,417 Crore, trading at ₹1393.40 on the NSE. Market cap moves with the live share price.
What is Senores Pharmaceuticals's P/E ratio?
Senores Pharmaceuticals's trailing twelve-month P/E ratio is 52.8x, with a price-to-book (P/B) of 5.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Senores Pharmaceuticals?
Senores Pharmaceuticals runs a net profit margin of 18.5%, a gross margin of 59.6%, and an operating margin of 24.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Senores Pharmaceuticals generate?
Senores Pharmaceuticals reported revenue of ₹633 Crore for fiscal year 2025, with net income of ₹115 Crore and earnings per share (EPS) of 26.39. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Senores Pharmaceuticals pay a dividend?
Senores Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Senores Pharmaceuticals financially healthy?
Senores Pharmaceuticals carries a debt-to-equity ratio of 0.37x and a current ratio of 1.92x, with a market beta of 0.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Senores Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Senores Pharmaceuticals (SENORES) the key facts are: market cap ₹6,417 Crore, P/E 52.8x, revenue ₹633 Crore, 52-week range 601.1-1509.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Senores Pharmaceuticals's full fundamentals live
Get Senores Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.